5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 1192-1204

  Füller, Mathias ^a   Klein, Miriam ^a   Schmidt, Eva ^a   Rohde, Christian ^b   Göllner, Stefanie ^b   Schulze, Isabell ^b   Qianli, Jiang ^a   Berdel, Wolfgang E ^a   Edemir, Bayram ^b   Müller Tidow, Carsten ^b   Tschanter, Petra ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 azacytidine; Acute myeloid leukemia; DNA methyltransferase inhibition; Non small cell lung cancer; Synergism

Indexed keywords

AZACITIDINE; BROXURIDINE; CASPASE 3; CISPLATIN; CYTARABINE; ETOPOSIDE; GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION ASSAY; CPG ISLAND; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL LINE; LOW DRUG DOSE; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; LUNG NEOPLASMS; TUMOR CELL CULTURE; U937 CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CPG ISLANDS; DNA METHYLATION; DRUG SYNERGISM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUNG NEOPLASMS; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 84921906992     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2792     Document Type: Article

References (57)

1. th 2014]. Available from: http://seer. cancer.gov/statfacts/.
2. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
3. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
4. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007.
5. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW and Ehrlich M: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11: 6883-6894, 1983.
6. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
7. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
8. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
9. Pradhan S, Bacolla A, Wells RD and Roberts RJ: Recombinant human DNA (cytosine-5) methyltransferase. I. expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 274: 33002-33010, 1999.
10. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
11. Okano M, Xie S and Li E: Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19: 219-220, 1998.
12. Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257, 1999.
13. Ehrlich M: DNA hypomethylation in cancer cells. Epigenomics 1: 239-259, 2009.
14. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J and Belinsky SA: Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 68: 9005-9014, 2008.
15. Hollenbach PW, Nguyen AN, Brady H, et al: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: e9001, 2010.
16. Cihak A: Biological effects of 5-azacytidine in eukaryotes. Oncology 30: 405-422, 1974.
17. Tsai HC, Li H, Van Neste L, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21: 430-446, 2012.
18. Hagemann S, Heil O, Lyko F and Brueckner B: Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 6: e17388, 2011.
19. Hascher A, Haase AK, Hebestreit K, et al: DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res 20: 814-812, 2014.
20. Flotho C, Claus R, Batz C, et al: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23: 1019-1028, 2009.
21. Vidaza: EPAR - product information (Internet); January 3, 2014; cited February 6, 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000978/WC500050239.pdf.
22. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
23. Festuccia C, Gravina GL, D'Alessandro AM, et al: Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer 16: 401-413, 2009.
24. Tikoo K, Ali IY, Gupta J and Gupta C: 5-azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett 191: 158-166, 2009.
25. Francia G, Green SK, Bocci G, et al: Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther 4: 1484-1494, 2005.
26. Efferth T, Futscher BW and Osieka R: 5-azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs. Blood Cells Mol Dis 27: 637-648, 2001.
27. Kong XB, Tong WP and Chou TC: Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol 39: 250-257, 1991.
28. Asano T, Nakamura K, Fujii H, et al: Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation. Br J Cancer 92: 1486-1492, 2005.
29. Murakami T, Li X, Gong J, Bhatia U, Traganos F and Darzynkiewicz Z: Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 55: 3093-3098, 1995.
30. Cross M and Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64: 271-280, 1991.
31. Khan R, Schmidt-Mende J, Karimi M, et al: Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 36: 149-157, 2008.
32. Abbruzzese JL and Frost P: Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol 30: 31-36, 1992.
33. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G and Issa JP: Effect of AraC and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13: 4225-4232, 2007.
34. Issa JP and Kantarjian HM: Targeting DNA methylation. Clin Cancer Res 15: 3938-3946, 2009.
35. Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R: Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044, 2000.
36. Gius D, Cui H, Bradbury CM, et al: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361-371, 2004.
37. Gu C, Lu J, Cui T, et al: Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One 8: e72633, 2013.
38. Su Y, Xu H, Xu Y, Yu J, Xian Y and Luo Q: Azacytidine inhibits the proliferation of human promyelocytic leukemia cells (HL60) by demethylation of MGMT, DAPK and p16 genes. Hematology 17: 41-46, 2012.
39. Dmitriev AA, Kashuba VI, Haraldson K, et al: Genetic and epigenetic analysis of non-small cell lung cancer with NotImicroarrays. Epigenetics 7: 502-513, 2012.
40. Dunwell TL, Hesson LB, Pavlova T, et al: Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 4: 185-193, 2009.
41. Addou-Klouche L, Adelaide J, Finetti P, et al: Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer 9: 213. doi: 10.1186/1476-4598-9-213.
42. Chen SC, Lin CY, Chen YH, et al: Aberrant promoter methylation of EDNRB in lung cancer in Taiwan. Oncol Rep 15: 167-172, 2006.
43. Toyooka KO, Toyooka S, Virmani AK, et al: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61: 4556-4560, 2001.
44. Finger EC, Turley RS, Dong M, How T, Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29: 528-535, 2008.
45. Deng G, Nguyen A, Tanaka H, et al: Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer 118: 2999-3005, 2006.
46. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413, 2002.
47. Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T and Ogawa O: Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology 71: 1220-1225, 2008.
48. Eklund H, Uhlin U, Farnegardh M, Logan DT and Nordlund P: Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol 77: 177-268, 2001.
49. Lu AG, Feng H, Wang PX, Han DP, Chen XH and Zheng MH: Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. World J Gastroenterol 18: 4704-4713, 2012.
50. Morikawa T, Hino R, Uozaki H, et al: Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol 41: 1742-1748, 2010.
51. Klisovic RB, Blum W, Wei X, et al: Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 14: 3889-3895, 2008.
52. Aimiuwu J, Wang H, Chen P, et al: RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 119: 5229-5238, 2012.
53. Rauscher F III and Cadman E: Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res 43: 2688-2693, 1983.
54. Gray SG, Baird AM, O'Kelly F, et al: Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int J Mol Med 30: 1505-1511, 2012.
55. Smith SL and Douglas KT: Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin. Biochem Biophys Res Commun 162: 715-723, 1989.
56. Ellerhorst JA, Frost P, Abbruzzese JL, Newman RA and Chernajovsky Y: 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 67: 209-215, 1993.
57. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530, 1996.